Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial

Massimo Cristofanilli, MD
Published: Saturday, Oct 20, 2018



Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor (HR)-positive, HER2-negative breast cancer.

Phase III results from the PALOMA-3 trial, which investigated palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with HR-positive, HER2-negative breast cancer, were presented at the 2018 ESMO Congress. At a median follow-up of 44.8 months, a 6.6-month progression-free survival benefit for palbociclib/fulvestrant was maintained for overall survival at 6.9 months. Cristofanilli, lead author of PALOMA-3, reports that these findings confirm the use of palbociclib plus fulvestrant as the standard of care in this population.

In 2016, the FDA approved palbociclib in combination with fulvestrant for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. The approval was based on initial data from this study.

<<< 2018 ESMO Congress


Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor (HR)-positive, HER2-negative breast cancer.

Phase III results from the PALOMA-3 trial, which investigated palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with HR-positive, HER2-negative breast cancer, were presented at the 2018 ESMO Congress. At a median follow-up of 44.8 months, a 6.6-month progression-free survival benefit for palbociclib/fulvestrant was maintained for overall survival at 6.9 months. Cristofanilli, lead author of PALOMA-3, reports that these findings confirm the use of palbociclib plus fulvestrant as the standard of care in this population.

In 2016, the FDA approved palbociclib in combination with fulvestrant for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. The approval was based on initial data from this study.

<<< 2018 ESMO Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x